10 June 2025
2024 was a remarkable year for All.Can Belgium in many ways. Our actions attracted considerable attention, particularly from policymakers. In this annual report, we’ve brought everything together for you.
>> Download our 2024 annual report here <<
2024 was a remarkable year for All.Can Belgium in many ways. We kicked off the election year with our policy memorandum, offering concrete recommendations to policymakers on how to make cancer care in Belgium even more effective and patient-centered.
A few months later, we raised awareness about sarcoma with patient testimonials and interviews of medical experts. In June, during our General Assembly, we discussed new insights into the treatment of operable non-small cell lung cancer and, more broadly, the healthcare challenges facing the new governments.
In early November, we hosted our first large-scale conference, “Cancer Care: The Future Is Now”, focusing on both groundbreaking advances in cancer research and practice and the policies needed to bring these innovations to patients.
Also in November, we launched the “Clear the Air on Lung Cancer” campaign together with Prolong, ALK Positive Belgium, and the other members of our lung cancer working group. For a month, we shared powerful stories from patients, caregivers, and researchers. Mid-November, we also organized an event for the general public at Brussels Central Station, which attracted national and continued the conversation on national television.
We concluded the year with the publication of our whitepaper on lung cancer screening, highlighting the pros and cons of a national screening program and formulated well-reasoned recommendations for policymakers.
And these are just the highlights from 2024…
What do we see as the most important achievement in this entire series? Not a single action or publication, but the fact that All.Can Belgium is increasingly being recognized as a reliable partner in Belgian cancer care.
Thanks to our unique multi-stakeholder approach, we bring together all the key perspectives—patients, healthcare providers, policymakers, researchers, industry representatives, and more. Together, we are shaping a shared vision for the future of cancer care in our country.
All with one goal in mind: to truly make a difference for cancer patients.
Every year, almost 9,000 women [1] undergo a cone biopsy to treat precancerous lesions. Precancerous lesions are abnormal cells in the cervix that can develop into cervical cancer. They are detected through cervical screening. A cone biopsy is preceded by a colposcopy – a closer examination of the cervix. In…
Anal cancer is rare, almost always linked to HPV, and in many cases preventable — if we detect precancerous lesions in time. In an in-depth interview, Dr. Magali Surmont (UZ Brussels) shares how Belgium is taking action against anal cancer. She points to three key areas where we can truly…
Since January 2025, cervical cancer screening for women aged 30 and over has been carried out differently. The smear is now first tested for the presence of human papillomavirus (HPV), and only then, depending on the result of that first test, are the cells examined. There is a good reason…
